Miyashita N, Fukano H, Niki Y, Matsushima T
Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama 701-0192, Japan.
J Antimicrob Chemother. 2001 Sep;48(3):403-5. doi: 10.1093/jac/48.3.403.
The in vitro activity of telithromycin, a new ketolide, was compared with those of roxithromycin, azithromycin, clarithromycin and erythromycin A against 20 strains of Chlamydia pneumoniae. The MICs and minimal chlamydiacidal concentrations of telithromycin for the 20 C. pneumoniae strains both ranged between 0.031 and 0.25 mg/L. Telithromycin was twice as active as roxithromycin, azithromycin and erythromycin A, but less active than clarithromycin. These results appear to indicate that telithromycin is an effective antibiotic that should play some role in the treatment of respiratory tract infections caused by C. pneumoniae.
将新型酮内酯类药物泰利霉素的体外活性与罗红霉素、阿奇霉素、克拉霉素及红霉素A针对20株肺炎衣原体的活性进行了比较。泰利霉素对这20株肺炎衣原体的最低抑菌浓度（MIC）和最小杀衣原体浓度均在0.031至0.25mg/L之间。泰利霉素的活性是罗红霉素、阿奇霉素及红霉素A的两倍，但低于克拉霉素。这些结果似乎表明，泰利霉素是一种有效的抗生素，在治疗由肺炎衣原体引起的呼吸道感染中应能发挥一定作用。
